2023
Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison group
2019
Updates on Chronic HBV: Current Challenges and Future Goals
Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options In Gastroenterology 2019, 17: 271-291. PMID: 31077059, DOI: 10.1007/s11938-019-00236-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTenofovir alafenamide fumarateGlobal public health problemPublic health problemChronic HBVHepatocellular carcinomaLiver failureCurative treatmentLiver diseaseAntiviral therapyClinical trialsHealth problemsLaboratory safety parametersNew treatment recommendationsAdvanced liver diseaseComplications of cirrhosisCurrent antiviral therapiesEarly phase studiesLong-term useNucleotide analog drugsHBV reactivationLiver decompensationFunctional cureTherapeutic armamentariumTreatment recommendationsImproved outcomesVitamin E in Nonalcoholic Fatty Liver Disease
Banini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. Nutrition And Health 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.ChaptersNonalcoholic fatty liver diseaseVitamin E supplementationChronic liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseE supplementationVitamin ESubtype of NAFLDAnnual direct medical costsChronic viral hepatitisAlcoholic liver diseaseClinical practice guidelinesDirect medical costsLong-term useNAFLD patientsLabel treatmentViral hepatitisPharmacological therapyComplex pathogenesisHistological featuresLiver fibrosisClinical trialsLeading causeClinical studies
2016
Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics 2016, 8: cmt.s18885. PMID: 28670148, PMCID: PMC5491796, DOI: 10.4137/cmt.s18885.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonalcoholic fatty liver diseaseLiver diseaseManagement of NAFLDPathogenesis of NAFLDAdvanced phase clinical trialsLiver-related outcomesCornerstone of treatmentFirst-line therapyHigh-risk patientsChronic liver diseaseFatty liver diseaseCurrent treatment optionsHepatic manifestationNAFLD patientsMetabolic syndromeMajor etiologyInsulin resistancePharmacologic interventionsTreatment optionsClinical evaluationClinical trialsHigh riskVitamin ENatural historyPatients